Pulmatrix logo
Pulmatrix
PULM | NASDAQ
Chart Builder DCF Calculator
$1.29
$0.00 (0.00%)
At close: Nov 16, 2026, 3:59 PM ET
$1.31
+$0.02 (+1.55%)
After-hours: Nov 16, 2026, 6:15 PM ET

Pulmatrix Company Profile

Company profile explained

Company Profile

Pulmatrix, Inc. (PULM) is a clinical-stage biotechnology firm focused on creating and advancing inhaled treatments. The company's primary goal is to address significant unmet medical needs in respiratory and other diseases within the United States. Central to their approach is the innovative iSPERSE (inhaled small particles easily respirable and emitted) technology. This proprietary platform allows for the precise delivery of both small and large molecule therapeutics directly into the lungs, achieving either localized effects or systemic distribution throughout the body. Pulmatrix's development pipeline includes several key candidates: Pulmazole: An inhaled antifungal drug being developed to treat allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis. PUR1800: A narrow spectrum kinase inhibitor currently undergoing Phase 1b clinical trials for individuals suffering from stable moderate-to-severe chronic obstructive pulmonary disease (COPD). PUR3100: An iSPERSE-formulated version of dihydroergotamine, intended for the rapid relief of acute migraine attacks. The company also maintains strategic collaborations, including a licensing arrangement with RespiVert Ltd. for access to a range of kinase inhibitor drug candidates, a partnership with Cipla Technologies LLC for the development and commercialization of Pulmazole, and a collaboration and license agreement with Sensory Cloud, Inc. Established in 2003, Pulmatrix, Inc. is headquartered in Lexington, Massachusetts.

Key Executives

Name Position
Peter Ludlum Interim Chief Executive Officer & Interim Chief Financial Officer
Alexander Klibanov Founder

Latest SEC Filings

Date Type Title
Oct 30, 2026 425 Filing
Oct 27, 2026 8-K Current Report
Oct 26, 2026 424B3 Filing
Oct 22, 2026 EFFECT Filing
Oct 22, 2026 425 Filing
Oct 13, 2026 425 Filing
Oct 07, 2026 424B3 Filing
Oct 07, 2026 DEFA14A Filing
Oct 05, 2026 ARS Filing
Oct 05, 2026 S-3/A [Amend] Filing
View All SEC Filings ➞
Pulmatrix
Pulmatrix logo
Country United States
IPO Date Mar 21, 2014
Industry Biotechnology
Sector Healthcare
Employees 2
CEO Peter Ludlum

Contact Details

945 Concord Street Framingham, Massachusetts 01701 United States

Stock Details

Ticker Symbol PULM
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001574235
CUSIP Number 74584P301
ISIN Number US74584P3010
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.